Bimatoprost
Brand name: Lumigan
Rank #64 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$284.4M
Total Cost
610,243
Total Claims
$284.4M
Total Cost
9,710
Prescribers
$466
Cost per Claim
133,958
Beneficiaries
1,059,475
30-Day Fills
$29K
Avg Cost/Provider
63
Avg Claims/Provider
Share of Medicare Part D Spending
0.10%
of total Medicare Part D spending
$284.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $284.4M total
Top Prescribers of Bimatoprost
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Hamideh Moayedpardazi | Ophthalmology | Montebello, CA | 3,845 | $1.8M |
| 2 | Howard Kushnick | Ophthalmology | Allentown, PA | 2,525 | $1.4M |
| 3 | Scott Schecter | Optometry | Fort Lauderdale, FL | 2,530 | $1.2M |
| 4 | Fiaz Zaman | Ophthalmology | Houston, TX | 1,762 | $1.1M |
| 5 | Jorge Rivera | Ophthalmology | Mayaguez, PR | 3,756 | $940K |
| 6 | Benjamin Mandel | Ophthalmology | Montebello, CA | 2,381 | $922K |
| 7 | Analisa Arosemena | Ophthalmology | Miami Beach, FL | 2,777 | $867K |
| 8 | Milton Hearing | Optometry | Palm Springs, FL | 2,667 | $794K |
| 9 | Jacqueline Dauhajre | Ophthalmology | Jackson Heights, NY | 1,439 | $681K |
| 10 | Bingjing Roberts | Ophthalmology | New York, NY | 1,385 | $654K |
| 11 | David Mora | Optometry | Laredo, TX | 895 | $634K |
| 12 | Douglas Day | Ophthalmology | Atlanta, GA | 1,018 | $631K |
| 13 | Eugene Saravitz | Ophthalmology | Bethlehem, PA | 991 | $580K |
| 14 | Barbara Marsh | Ophthalmology | Albuquerque, NM | 1,141 | $562K |
| 15 | Juan Maldonado-Melendez | Ophthalmology | Arecibo, PR | 2,210 | $560K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
| 67 | Selexipag (Uptravi) | $279.1M | 12,320 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology